StockpollyBeta
Get App
Popularity #2,346
TSHA · NASDAQ · Biotechnology

Taysha Gene Therapies (TSHA)

Advances TSHA-102, an AAV9 gene therapy in pivotal testing for Rett syndrome.

$5.28
After-hours close+0.13 (+2.45%)
At close$5.16(+2.28%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue543122220500
Cost of revenue000000000000
Gross profit443122220500
202028222822242934334347
Research & development121321151515162025253439
87778789891012
General & administrative07778789891012
Other expenses00005000000−3
Operating income−16−16−24−21−26−20−21−27−34−28−43−47
−101640001001011
Interest income122122123332
Interest expense110000000000
Other non-operating income100−65000−100−10−1−1
Income before tax−11748−24−21−26−19−22−27−33−28−42−47
Net income from continuing operations−11748−24−21−26−19−22−27−33−28−42−47
Net income−11748−24−21−26−19−22−27−33−28−42−47
EPS, basic−$0.93$0.26−$0.10−$0.09−$0.10−$0.09−$0.08−$0.09−$0.09−$0.08−$0.12−$0.13
EPS, diluted−$0.93$0.26−$0.10−$0.09−$0.10−$0.09−$0.08−$0.09−$0.09−$0.08−$0.12−$0.13
Weighted average shares, basic126187231233268205269298353320367369
Weighted average shares, diluted126187231233268205269298353320367369
EBITDA−11549−24−21−25−18−21−27−32−28−42−46
Depreciation & amortization000000000000
EBIT−11648−24−21−26−19−22−27−33−28−42−47